ReviewClinical epigenetics2025
What's counted counts: the implications of underrepresentation for the application of epigenetic clocks in diverse populations.
Review in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- The BHARAT study: a multi-modal, multi-omics investigation of aging signatures in the Indian population.Aging · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DNA methylation (DNAm) has been touted as a potential unified marker of the contributions of both inherited and environmental factors on an individual's health. Changes in DNAm have been associated with several chronic diseases and mortality, and DNAm risk scores, or epigenetic clocks, have been proposed as metrics to quantify the process of 'biological ageing'. Unfortunately, research involving epigenetic clocks is not free from the issues faced in other fields of genomic research. Namely, individuals of European ancestry make up the vast majority of epigenetic study participants and it is unclear whether epigenetic clocks will provide equitable benefits when applied in diverse populations. Although some studies have reported variation in DNAm between populations, it can be difficult to identify the mechanisms underlying these differences. This has implications for clinical application of epigenetic clocks. In this review, we discuss epigenetic clocks, missing diversity in epigenetic research and the potential consequences of the latter on the equitable translation of epigenetic clocks to diverse populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.